Vertebral Compression Fracture Market Size, Share, & Trends Analysis - Global - 2025-2031 - Includes: Vertebroplasty and Percutaneous Vertebral Augmentation Markets
Description
Global Vertebral Compression Fracture (VCF) Market Report, 2025 Edition
Executive Summary
The global vertebral compression fracture (VCF) device market was valued at over $1.1 billion in 2024. The market is expected to grow at a compound annual growth rate (CAGR) of 5.2 percent, reaching over $1.6 billion by 2032.
This report covers percutaneous vertebral augmentation (PVA) and vertebroplasty. It quantifies unit sales, average selling prices (ASPs), market values, growth rates, and company shares, and analyzes market drivers and limiters, mergers and acquisitions, and technology trends. The report provides historical data to 2022 and forecasts through 2032.
The scope reflects how healthcare providers use minimally invasive, cement-based spinal repair procedures to treat vertebral compression fractures caused by osteoporosis, trauma, or malignancy. Growth is supported by increasing awareness, favorable reimbursement, and procedural advantages over open surgery, while conservative treatments and cement-related complications act as key restraints.
Market Overview
Vertebral compression fractures are among the most common fractures in elderly patients, often resulting from osteoporosis or cancer-related bone fragility. Untreated, these fractures cause severe pain, spinal deformity, and reduced quality of life.
Minimally invasive treatments such as vertebroplasty and percutaneous vertebral augmentation (PVA) have become the standard of care for many patients. These techniques involve injecting bone cement into the vertebra to stabilize the fracture and relieve pain. Kyphoplasty, a form of PVA, also restores partial vertebral height before cement injection, helping correct deformity.
Growth is driven by the clinical benefits of these procedures, including faster recovery, shorter hospital stays, and reduced pain compared to open surgery. Both vertebroplasty and kyphoplasty are performed under imaging guidance, allowing treatment even in frail or elderly patients who are not candidates for traditional surgery.
Regional performance varies by market maturity. North America remains the largest region due to established procedural infrastructure and strong reimbursement. Asia-Pacific holds the second-largest share, driven by its large aging population and improved access to spine care. The Middle East is projected to experience the highest growth rate over the forecast period, followed by Africa and Asia-Pacific. Western Europe maintains steady performance, while its more mature market moderates overall growth compared to emerging regions.
Market Drivers
Vertebral Height Restoration
Kyphoplasty and other percutaneous vertebral augmentation techniques restore vertebral height and correct kyphotic deformity, which improves posture and pain management. The ability to restore anatomy and stability contributes to strong patient preference for PVA over vertebroplasty in many markets. Reimbursement systems in North America and Europe further favor kyphoplasty, as procedure payments are often higher than for vertebroplasty.
Minimally Invasive Treatment
Both vertebroplasty and PVA are percutaneous, minimally invasive procedures that provide rapid pain relief with lower complication rates compared to open surgery. This is especially important for older patients and those with fragile bones. The reduced recovery time, shorter hospitalization, and lower overall morbidity make these options appealing for patients and providers alike.
The large eligible patient population includes individuals who cannot withstand open surgical repair, as well as younger patients with traumatic compression fractures. As patient and physician awareness increases, the adoption of these procedures continues to expand globally.
Favorable Reimbursement
Both PVA and vertebroplasty benefit from established reimbursement coverage in most developed healthcare systems. In North America and Western Europe, these procedures are widely reimbursed under public and private insurance programs. Reimbursement positively influences procedural volume because it reduces out-of-pocket cost and aligns hospital incentives toward minimally invasive options.
Kyphoplasty in particular benefits from more favorable reimbursement compared to vertebroplasty, reflecting its higher procedural complexity and cost. This financial structure supports continued investment in PVA device innovation and procedural training.
Aging Population
The growing prevalence of osteoporosis and other age-related bone conditions is a key demand driver. As global populations age, fracture incidence rises, expanding the addressable market for vertebral augmentation and vertebroplasty systems. Increased screening and earlier diagnosis of vertebral fractures further contribute to procedure growth across all regions.
Market Limiters
Clinical Complications
The most common complication associated with VCF procedures is cement leakage, which can occur when cement escapes into surrounding tissues or the spinal canal. In severe cases, this can compress spinal nerves or cause toxicity, occasionally requiring revision surgery. Although newer delivery systems and more viscous cement formulations have significantly reduced leakage rates, ongoing vigilance remains necessary.
Other potential complications, such as embolism or infection, remain rare but continue to drive research into safer materials and refined delivery methods.
Conservative Treatments
A major challenge to VCF market growth is the ongoing use of conservative, non-surgical management. Many fractures heal naturally with rest, medication, or bracing within several months. In these cases, interventional procedures may not be deemed necessary. This preference for non-invasive care limits procedural growth, particularly in regions where diagnostic rates are low or where patients delay treatment due to cost or limited access to specialists.
Pricing Pressure in Mature Markets
In regions such as North America and Western Europe, competitive pricing, group purchasing organizations (GPOs), and established supplier relationships place downward pressure on ASPs. Mature procurement systems favor vendors offering value-based packages that include cement, balloons, and delivery systems. While this benefits hospitals through lower costs, it limits margin expansion for manufacturers.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, market forecasts, market growth rates, units sold, and average selling prices.
Qualitative Coverage
Market growth trends, limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, FDA recalls, disruptive technologies, and disease overviews shaping demand for VCF devices.
Time Frame
Base year 2024, forecasts 2025 to 2032, historical data 2022 to 2024.
Data Sources
Primary interviews with orthopedic surgeons and interventional radiologists, regulatory data, hospital purchasing data, import and export statistics, and iData Research’s internal database.
Method Note
Revenue is modeled from units multiplied by ASP, validated with procedure data and replacement rates by region.
Care Settings
Hospitals, specialty spine centers, and interventional radiology suites performing vertebroplasty and PVA procedures.
Markets Covered and Segmentation
Vertebral Compression Fracture (VCF) Device Market – Further Segmented Into:
Vertebroplasty
Percutaneous Vertebral Augmentation (PVA)
Each segment is analyzed for unit sales, ASPs, and market value trends across all major regions, with detailed forecasts to 2032.
Competitive Analysis
Medtronic held the leading position in the global VCF market in 2024, accounting for nearly half of total market value. The company maintains leadership across most regions, driven by its extensive product line and strong brand recognition. Medtronic’s Kyphon® and KyphX® balloon systems dominate the PVA segment, supported by a range of compatible bone cements and delivery systems. Its established distribution and training programs continue to support procedural adoption globally.
Stryker ranked as the second-largest competitor in 2024. The company’s portfolio includes the AutoPlex™ cement mixer and delivery system, VertaPlex™, VertaPlex HV™, and SpinePlex® bone cements. Together, these products form Stryker’s comprehensive vertebroplasty offering. The iVAS™ PVA system and AVAflex® Balloon System strengthen its position in vertebral augmentation. The lower cost of Stryker’s systems compared to Medtronic’s KyphX® has helped it capture share, especially in price-sensitive markets. The AVAmax® system further broadens its procedural options, enhancing Stryker’s competitiveness in hospitals and ambulatory centers.
DePuy Synthes ranked third globally, with a diversified portfolio across both vertebroplasty and kyphoplasty. Its key products include the CONFIDENCE™ Spinal Cement System and VERTECEM™ V+ bone cement, designed for controlled delivery and enhanced stability. DePuy Synthes’ strong presence in North America and Europe underpins its performance, while strategic investment in emerging markets and continued product innovation are expected to expand its global footprint over the forecast period.
Overall, the VCF market is concentrated, with Medtronic and Stryker collectively representing the majority of market value. DePuy Synthes and a smaller group of regional manufacturers compete primarily on cost and distribution strength in emerging markets.
Technology and Practice Trends
Balloon-based augmentation remains the dominant method for restoring vertebral height and reducing pain, particularly in kyphoplasty.
Cement formulation advances improve viscosity control and reduce leakage risk.
Image-guided systems using fluoroscopy and 3D navigation enhance placement accuracy.
Single-use kits streamline procedural preparation and limit cross-contamination.
Minimally invasive access instruments continue to reduce procedure time and recovery duration.
Emerging biomaterials, including bioresorbable cements and polymers, are being studied to improve long-term outcomes.
Training and certification programs expand the qualified surgeon base, increasing global procedural capacity.
Geography
This edition provides global coverage for North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
Why This Report
Where are the largest and fastest-growing opportunities within the VCF market by device type and region
How do reimbursement and procedural trends influence PVA versus vertebroplasty adoption
What are the key technological innovations improving procedural safety and reducing cement leakage
How are pricing pressures and procurement policies affecting ASPs in mature markets
Which companies—Medtronic, Stryker, and DePuy Synthes—lead the market and how do their portfolios differ
What is the impact of conservative treatment alternatives on procedural demand in emerging economies
How do regional adoption patterns align with healthcare infrastructure and demographic trends
The Global Vertebral Compression Fracture Device Market Report from iData Research answers these questions with procedure-based models, company share analysis, and pricing detail. Use it to quantify demand, plan portfolio strategy, and guide investment or product development decisions.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows
Executive Summary
The global vertebral compression fracture (VCF) device market was valued at over $1.1 billion in 2024. The market is expected to grow at a compound annual growth rate (CAGR) of 5.2 percent, reaching over $1.6 billion by 2032.
This report covers percutaneous vertebral augmentation (PVA) and vertebroplasty. It quantifies unit sales, average selling prices (ASPs), market values, growth rates, and company shares, and analyzes market drivers and limiters, mergers and acquisitions, and technology trends. The report provides historical data to 2022 and forecasts through 2032.
The scope reflects how healthcare providers use minimally invasive, cement-based spinal repair procedures to treat vertebral compression fractures caused by osteoporosis, trauma, or malignancy. Growth is supported by increasing awareness, favorable reimbursement, and procedural advantages over open surgery, while conservative treatments and cement-related complications act as key restraints.
Market Overview
Vertebral compression fractures are among the most common fractures in elderly patients, often resulting from osteoporosis or cancer-related bone fragility. Untreated, these fractures cause severe pain, spinal deformity, and reduced quality of life.
Minimally invasive treatments such as vertebroplasty and percutaneous vertebral augmentation (PVA) have become the standard of care for many patients. These techniques involve injecting bone cement into the vertebra to stabilize the fracture and relieve pain. Kyphoplasty, a form of PVA, also restores partial vertebral height before cement injection, helping correct deformity.
Growth is driven by the clinical benefits of these procedures, including faster recovery, shorter hospital stays, and reduced pain compared to open surgery. Both vertebroplasty and kyphoplasty are performed under imaging guidance, allowing treatment even in frail or elderly patients who are not candidates for traditional surgery.
Regional performance varies by market maturity. North America remains the largest region due to established procedural infrastructure and strong reimbursement. Asia-Pacific holds the second-largest share, driven by its large aging population and improved access to spine care. The Middle East is projected to experience the highest growth rate over the forecast period, followed by Africa and Asia-Pacific. Western Europe maintains steady performance, while its more mature market moderates overall growth compared to emerging regions.
Market Drivers
Vertebral Height Restoration
Kyphoplasty and other percutaneous vertebral augmentation techniques restore vertebral height and correct kyphotic deformity, which improves posture and pain management. The ability to restore anatomy and stability contributes to strong patient preference for PVA over vertebroplasty in many markets. Reimbursement systems in North America and Europe further favor kyphoplasty, as procedure payments are often higher than for vertebroplasty.
Minimally Invasive Treatment
Both vertebroplasty and PVA are percutaneous, minimally invasive procedures that provide rapid pain relief with lower complication rates compared to open surgery. This is especially important for older patients and those with fragile bones. The reduced recovery time, shorter hospitalization, and lower overall morbidity make these options appealing for patients and providers alike.
The large eligible patient population includes individuals who cannot withstand open surgical repair, as well as younger patients with traumatic compression fractures. As patient and physician awareness increases, the adoption of these procedures continues to expand globally.
Favorable Reimbursement
Both PVA and vertebroplasty benefit from established reimbursement coverage in most developed healthcare systems. In North America and Western Europe, these procedures are widely reimbursed under public and private insurance programs. Reimbursement positively influences procedural volume because it reduces out-of-pocket cost and aligns hospital incentives toward minimally invasive options.
Kyphoplasty in particular benefits from more favorable reimbursement compared to vertebroplasty, reflecting its higher procedural complexity and cost. This financial structure supports continued investment in PVA device innovation and procedural training.
Aging Population
The growing prevalence of osteoporosis and other age-related bone conditions is a key demand driver. As global populations age, fracture incidence rises, expanding the addressable market for vertebral augmentation and vertebroplasty systems. Increased screening and earlier diagnosis of vertebral fractures further contribute to procedure growth across all regions.
Market Limiters
Clinical Complications
The most common complication associated with VCF procedures is cement leakage, which can occur when cement escapes into surrounding tissues or the spinal canal. In severe cases, this can compress spinal nerves or cause toxicity, occasionally requiring revision surgery. Although newer delivery systems and more viscous cement formulations have significantly reduced leakage rates, ongoing vigilance remains necessary.
Other potential complications, such as embolism or infection, remain rare but continue to drive research into safer materials and refined delivery methods.
Conservative Treatments
A major challenge to VCF market growth is the ongoing use of conservative, non-surgical management. Many fractures heal naturally with rest, medication, or bracing within several months. In these cases, interventional procedures may not be deemed necessary. This preference for non-invasive care limits procedural growth, particularly in regions where diagnostic rates are low or where patients delay treatment due to cost or limited access to specialists.
Pricing Pressure in Mature Markets
In regions such as North America and Western Europe, competitive pricing, group purchasing organizations (GPOs), and established supplier relationships place downward pressure on ASPs. Mature procurement systems favor vendors offering value-based packages that include cement, balloons, and delivery systems. While this benefits hospitals through lower costs, it limits margin expansion for manufacturers.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, market forecasts, market growth rates, units sold, and average selling prices.
Qualitative Coverage
Market growth trends, limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, FDA recalls, disruptive technologies, and disease overviews shaping demand for VCF devices.
Time Frame
Base year 2024, forecasts 2025 to 2032, historical data 2022 to 2024.
Data Sources
Primary interviews with orthopedic surgeons and interventional radiologists, regulatory data, hospital purchasing data, import and export statistics, and iData Research’s internal database.
Method Note
Revenue is modeled from units multiplied by ASP, validated with procedure data and replacement rates by region.
Care Settings
Hospitals, specialty spine centers, and interventional radiology suites performing vertebroplasty and PVA procedures.
Markets Covered and Segmentation
Vertebral Compression Fracture (VCF) Device Market – Further Segmented Into:
Vertebroplasty
Percutaneous Vertebral Augmentation (PVA)
Each segment is analyzed for unit sales, ASPs, and market value trends across all major regions, with detailed forecasts to 2032.
Competitive Analysis
Medtronic held the leading position in the global VCF market in 2024, accounting for nearly half of total market value. The company maintains leadership across most regions, driven by its extensive product line and strong brand recognition. Medtronic’s Kyphon® and KyphX® balloon systems dominate the PVA segment, supported by a range of compatible bone cements and delivery systems. Its established distribution and training programs continue to support procedural adoption globally.
Stryker ranked as the second-largest competitor in 2024. The company’s portfolio includes the AutoPlex™ cement mixer and delivery system, VertaPlex™, VertaPlex HV™, and SpinePlex® bone cements. Together, these products form Stryker’s comprehensive vertebroplasty offering. The iVAS™ PVA system and AVAflex® Balloon System strengthen its position in vertebral augmentation. The lower cost of Stryker’s systems compared to Medtronic’s KyphX® has helped it capture share, especially in price-sensitive markets. The AVAmax® system further broadens its procedural options, enhancing Stryker’s competitiveness in hospitals and ambulatory centers.
DePuy Synthes ranked third globally, with a diversified portfolio across both vertebroplasty and kyphoplasty. Its key products include the CONFIDENCE™ Spinal Cement System and VERTECEM™ V+ bone cement, designed for controlled delivery and enhanced stability. DePuy Synthes’ strong presence in North America and Europe underpins its performance, while strategic investment in emerging markets and continued product innovation are expected to expand its global footprint over the forecast period.
Overall, the VCF market is concentrated, with Medtronic and Stryker collectively representing the majority of market value. DePuy Synthes and a smaller group of regional manufacturers compete primarily on cost and distribution strength in emerging markets.
Technology and Practice Trends
Balloon-based augmentation remains the dominant method for restoring vertebral height and reducing pain, particularly in kyphoplasty.
Cement formulation advances improve viscosity control and reduce leakage risk.
Image-guided systems using fluoroscopy and 3D navigation enhance placement accuracy.
Single-use kits streamline procedural preparation and limit cross-contamination.
Minimally invasive access instruments continue to reduce procedure time and recovery duration.
Emerging biomaterials, including bioresorbable cements and polymers, are being studied to improve long-term outcomes.
Training and certification programs expand the qualified surgeon base, increasing global procedural capacity.
Geography
This edition provides global coverage for North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
Why This Report
Where are the largest and fastest-growing opportunities within the VCF market by device type and region
How do reimbursement and procedural trends influence PVA versus vertebroplasty adoption
What are the key technological innovations improving procedural safety and reducing cement leakage
How are pricing pressures and procurement policies affecting ASPs in mature markets
Which companies—Medtronic, Stryker, and DePuy Synthes—lead the market and how do their portfolios differ
What is the impact of conservative treatment alternatives on procedural demand in emerging economies
How do regional adoption patterns align with healthcare infrastructure and demographic trends
The Global Vertebral Compression Fracture Device Market Report from iData Research answers these questions with procedure-based models, company share analysis, and pricing detail. Use it to quantify demand, plan portfolio strategy, and guide investment or product development decisions.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Reports are available with flexible licensing to fit commercial, strategy, and investment workflows
Table of Contents
97 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
